Recombinant Mouse CCL25/TECK Protein

R&D Systems, part of Bio-Techne | Catalog # 481-TK

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Carrier Free
481-TK-025/CF
Catalog #
Availability
Size / Price
Qty
With Carrier
481-TK-025
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

E. coli

Accession #

O35903.1

Conjugate

Unconjugated

Applications

Bioactivity

View all CCL25/TECK Proteins and Enzymes »

Product Specifications

Source

E. coli-derived mouse CCL25/TECK protein
Gln24-Asn144, with an N-terminal Met

Purity

>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met

Predicted Molecular Mass

14 kDa

SDS-PAGE

16-17 kDa doublet, reducing conditions

Activity

Measured by its ability to chemoattract BaF3 mouse pro-B cells transfected with human CCR9.
The ED50 for this effect is 0.1-0.5 µg/mL.

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 481-TK
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Carrier Free: 481-TK/CF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CCL25/TECK

CCL25, also known as TECK (thymus-expressed chemokine), is a CC chemokine that regulates the trafficking of lymphocytes in the thymus and small intestine. Mature mouse CCL25 shares 40% and 81% amino acid sequence identity with human and rat CCL25, respectively (1). CCL25 is produced by stromal cells in the thymus and epithelial cells of the small intestine, particularly the jejunum and ileum (1-3). It binds to and induces chemoattraction through CCR9 (1, 4, 5), and both human and mouse proteins act on human CCR9 (4). CCR9 is expressed on immature pre-T cells and thymocytes (5, 6). CCL25 induces the homing of several lymphocyte populations to the small intestine (3), including Integrin alpha4 beta7+ gamma delta T cells (6, 7), Integrin alphaE beta7+ CD8+ T cells (8), and IgA-producing plasma cells (2). In cancer, functional CCR9 mediates the metastasis of melanoma cells to the small intestine (9), contributes to the CCL25-dependent migration and invasion of some breast carcinomas (10), and attracts mesenchymal stromal cells to CCL25-expressing multiple myelomas (11). CCL25 contributes to the severity of chronic inflammation in rheumatoid arthritis where it attracts CCR9+ monocytes and macrophages (12), in endometriosis where it promotes the invasiveness of stromal cells (13), and in atherosclerosis where it contributes to the accumulation of CCR9+ macrophages in arterial plaques (14).

References

  1. Vicari, A.P. et al. (1997) Immunity 7:291.
  2. Bowman, E.P. et al. (2002) J. Exp. Med. 195:269.
  3. Kunkel, E.J. et al. (2000) J. Exp. Med. 192:761.
  4. Zaballos, A. et al. (1999) J. Immunol. 162:5671.
  5. Youn, B.-S. et al. (1999) Blood 94:2533.
  6. Uehara, S. et al. (2002) J. Immunol. 168:134.
  7. Costa, M.F.S. et al. (2012) Eur. J. Immunol. 42:1250.
  8. Svensson, M. et al. (2002) J. Clin. Invest. 110:1113.
  9. Amersi, F.F. et al. (2008) Clin. Cancer Res. 14:638.
  10. Johnson-Holiday, C. et al. (2011) Int. J. Oncol. 38:1279.
  11. Xu, S. et al. (2012) Stem Cells 30:266.
  12. Schmutz, C. et al. (2010) Arthritis Res. Ther. 12:R161.
  13. Wang, Y. et al. (2010) Cell. Mol. Immunol. 7:51.
  14. Alla, J.A. et al. (2010) J. Biol. Chem. 285:23496.

Alternate Names

TECK

Entrez Gene IDs

6370 (Human); 20300 (Mouse)

Gene Symbol

CCL25

UniProt

O35903.1

Additional CCL25/TECK Products

Product Documents for Recombinant Mouse CCL25/TECK Protein

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS 481-TK (with carrier)
Download SDS 481-TK/CF (carrier free)

Product Specific Notices for Recombinant Mouse CCL25/TECK Protein

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.